Neovascularity and clinical outcome in high-grade extremity soft tissue sarcomas. 1998

N C Saenz, and M J Heslin, and V Adsay, and J J Lewis, and D H Leung, and M P LaQuaglia, and M F Brennan
Department of Surgery, Memorial Sloan-Kettering Cancer Center, New York, New York 10021, USA.

BACKGROUND Increased tumor neovascularity has been shown to correlate with poor prognosis in solid tumors. METHODS Microvessels were identified by factor VIII immunohistochemical staining. Analysis of microvessel counts, tumor characteristics, and resection details was performed on 119 primary, high-grade extremity soft tissue sarcomas (STS) and correlated with clinical outcome. RESULTS Tumor characteristics and resection details were analyzed and patient outcome was examined with respect to local recurrence, distant metastasis, and disease-specific survival. Factors found to be significant on univariate analysis for all outcome variables were positive microscopic margin and tumor size. A positive microscopic margin was found to be a significant risk factor for local recurrence (P = .03), distant metastasis (P = .006), and disease-specific survival (P = .004). A primary tumor greater than 10 cm in diameter was a poor prognostic factor for distant metastasis (P = .03) and disease-specific survival (P = .006) when compared to tumors smaller than 10 cm. Microvessel count did not correlate with survival nor did it predict distant metastasis or local recurrence. Histologic subtypes of STS that have a prominent vascular pattern as a diagnostic criterion (i.e., angiosarcoma, liposarcoma, hemangiopericytoma) form a subgroup of all STS. Neovascularity in these subtypes showed no relationship to clinical outcome. CONCLUSIONS These data confirm the prognostic importance of microscopic margin and tumor size in high-grade extremity STS. Neovascularity measured by factor VIII staining had no prognostic significance in these mesenchymal tumors, in contradistinction to carcinomas. Alternatively, microvessel counts may not accurately represent the angiogenic capacity of STS. Therefore, patients with STS who are eligible for anti-angiogenesis clinical trials cannot be identified solely by microvessel count.

UI MeSH Term Description Entries
D008297 Male Males
D008875 Middle Aged An adult aged 45 - 64 years. Middle Age
D009367 Neoplasm Staging Methods which attempt to express in replicable terms the extent of the neoplasm in the patient. Cancer Staging,Staging, Neoplasm,Tumor Staging,TNM Classification,TNM Staging,TNM Staging System,Classification, TNM,Classifications, TNM,Staging System, TNM,Staging Systems, TNM,Staging, Cancer,Staging, TNM,Staging, Tumor,System, TNM Staging,Systems, TNM Staging,TNM Classifications,TNM Staging Systems
D009389 Neovascularization, Pathologic A pathologic process consisting of the proliferation of blood vessels in abnormal tissues or in abnormal positions. Angiogenesis, Pathologic,Angiogenesis, Pathological,Neovascularization, Pathological,Pathologic Angiogenesis,Pathologic Neovascularization,Pathological Angiogenesis,Pathological Neovascularization
D012008 Recurrence The return of a sign, symptom, or disease after a remission. Recrudescence,Relapse,Recrudescences,Recurrences,Relapses
D005121 Extremities The farthest or outermost projections of the body, such as the HAND and FOOT. Limbs,Extremity,Limb
D005260 Female Females
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000328 Adult A person having attained full growth or maturity. Adults are of 19 through 44 years of age. For a person between 19 and 24 years of age, YOUNG ADULT is available. Adults
D012509 Sarcoma A connective tissue neoplasm formed by proliferation of mesodermal cells; it is usually highly malignant. Sarcoma, Epithelioid,Sarcoma, Soft Tissue,Sarcoma, Spindle Cell,Epithelioid Sarcoma,Epithelioid Sarcomas,Sarcomas,Sarcomas, Epithelioid,Sarcomas, Soft Tissue,Sarcomas, Spindle Cell,Soft Tissue Sarcoma,Soft Tissue Sarcomas,Spindle Cell Sarcoma,Spindle Cell Sarcomas

Related Publications

N C Saenz, and M J Heslin, and V Adsay, and J J Lewis, and D H Leung, and M P LaQuaglia, and M F Brennan
November 1994, Journal of surgical oncology,
N C Saenz, and M J Heslin, and V Adsay, and J J Lewis, and D H Leung, and M P LaQuaglia, and M F Brennan
March 1998, European journal of cancer (Oxford, England : 1990),
N C Saenz, and M J Heslin, and V Adsay, and J J Lewis, and D H Leung, and M P LaQuaglia, and M F Brennan
August 2004, Journal of the College of Physicians and Surgeons--Pakistan : JCPSP,
N C Saenz, and M J Heslin, and V Adsay, and J J Lewis, and D H Leung, and M P LaQuaglia, and M F Brennan
May 2017, JMIR research protocols,
N C Saenz, and M J Heslin, and V Adsay, and J J Lewis, and D H Leung, and M P LaQuaglia, and M F Brennan
September 1988, Journal of clinical oncology : official journal of the American Society of Clinical Oncology,
N C Saenz, and M J Heslin, and V Adsay, and J J Lewis, and D H Leung, and M P LaQuaglia, and M F Brennan
January 1985, Progress in clinical and biological research,
N C Saenz, and M J Heslin, and V Adsay, and J J Lewis, and D H Leung, and M P LaQuaglia, and M F Brennan
July 1986, Cancer,
N C Saenz, and M J Heslin, and V Adsay, and J J Lewis, and D H Leung, and M P LaQuaglia, and M F Brennan
January 2020, The Journal of surgical research,
N C Saenz, and M J Heslin, and V Adsay, and J J Lewis, and D H Leung, and M P LaQuaglia, and M F Brennan
December 2007, Oncology reports,
N C Saenz, and M J Heslin, and V Adsay, and J J Lewis, and D H Leung, and M P LaQuaglia, and M F Brennan
June 2006, BMC cancer,
Copied contents to your clipboard!